A placebo-controlled trial of oral pyridoxine in hyperemesis gravidarum

Objective: To evaluate oral pyridoxine in conjunction with standard therapy in women hospitalized for hyperemesis gravidarum (HG). Methods: Patients with HG were randomized at hospitalization to 20 mg oral pyridoxine thrice daily or to placebo. Intravenous rehydration, metoclopramide and oral thiami...

Full description

Saved in:
Bibliographic Details
Main Authors: Tan, P.C., Yow, C.M., Omar, S.Z.
Format: Article
Language:English
Published: 2009
Subjects:
Online Access:http://eprints.um.edu.my/10851/1/Tan-2009-A_Placebo-Controlled.pdf
http://eprints.um.edu.my/10851/
http://www.karger.com/Article/Pdf/181182
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Universiti Malaya
Language: English
id my.um.eprints.10851
record_format eprints
spelling my.um.eprints.108512014-07-16T00:19:37Z http://eprints.um.edu.my/10851/ A placebo-controlled trial of oral pyridoxine in hyperemesis gravidarum Tan, P.C. Yow, C.M. Omar, S.Z. R Medicine Obstetrics Objective: To evaluate oral pyridoxine in conjunction with standard therapy in women hospitalized for hyperemesis gravidarum (HG). Methods: Patients with HG were randomized at hospitalization to 20 mg oral pyridoxine thrice daily or to placebo. Intravenous rehydration, metoclopramide and oral thiamine were also administered. Metoclopramide and thiamine were continued for 2 weeks after discharge. Rehospitalization for HG in the 2-week study period was ascertained, vomiting was recorded by diary, and nausea was evaluated with a 10-point visual analogue scale (VAS) at enrolment, after hospital discharge and on week 1 and 2 reviews. Results: Ninety-two women were included in the analysis. The rehospitalization rate was 37.5 versus 21.1 (relative risk 1.8, 95 confidence interval 0.9-3.7, p = 0.14) for pyridoxine and placebo, respectively. Daily vomiting episodes after discharge were not different (mean +/- SD): 1.9 +/- 2.4 versus 1.4 +/- 1.1, p = 0.28 during week 1 and 1.4 +/- 1.3 versus 1.4 +/- 1.6, p = 0.98 during week 2. Repeated-measures analysis of variance showed no difference in the nausea visual analogue scale (p = 0.59). Conclusion: The use of oral pyridoxine in conjunction with metoclopramide during the inpatient stay and during the 2 weeks after hospital discharge for hyperemesis gravidarum did not improve the rehospitalization rate, the vomiting frequency or the nausea score. Larger studies need to be done. Copyright (C) 2008 S. Karger AG, Basel 2009 Article PeerReviewed application/pdf en http://eprints.um.edu.my/10851/1/Tan-2009-A_Placebo-Controlled.pdf Tan, P.C. and Yow, C.M. and Omar, S.Z. (2009) A placebo-controlled trial of oral pyridoxine in hyperemesis gravidarum. Gynecologic and Obstetric Investigation, 67 (3). pp. 151-157. ISSN 0378-7346 http://www.karger.com/Article/Pdf/181182 10.1159/000181182
institution Universiti Malaya
building UM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Malaya
content_source UM Research Repository
url_provider http://eprints.um.edu.my/
language English
topic R Medicine
Obstetrics
spellingShingle R Medicine
Obstetrics
Tan, P.C.
Yow, C.M.
Omar, S.Z.
A placebo-controlled trial of oral pyridoxine in hyperemesis gravidarum
description Objective: To evaluate oral pyridoxine in conjunction with standard therapy in women hospitalized for hyperemesis gravidarum (HG). Methods: Patients with HG were randomized at hospitalization to 20 mg oral pyridoxine thrice daily or to placebo. Intravenous rehydration, metoclopramide and oral thiamine were also administered. Metoclopramide and thiamine were continued for 2 weeks after discharge. Rehospitalization for HG in the 2-week study period was ascertained, vomiting was recorded by diary, and nausea was evaluated with a 10-point visual analogue scale (VAS) at enrolment, after hospital discharge and on week 1 and 2 reviews. Results: Ninety-two women were included in the analysis. The rehospitalization rate was 37.5 versus 21.1 (relative risk 1.8, 95 confidence interval 0.9-3.7, p = 0.14) for pyridoxine and placebo, respectively. Daily vomiting episodes after discharge were not different (mean +/- SD): 1.9 +/- 2.4 versus 1.4 +/- 1.1, p = 0.28 during week 1 and 1.4 +/- 1.3 versus 1.4 +/- 1.6, p = 0.98 during week 2. Repeated-measures analysis of variance showed no difference in the nausea visual analogue scale (p = 0.59). Conclusion: The use of oral pyridoxine in conjunction with metoclopramide during the inpatient stay and during the 2 weeks after hospital discharge for hyperemesis gravidarum did not improve the rehospitalization rate, the vomiting frequency or the nausea score. Larger studies need to be done. Copyright (C) 2008 S. Karger AG, Basel
format Article
author Tan, P.C.
Yow, C.M.
Omar, S.Z.
author_facet Tan, P.C.
Yow, C.M.
Omar, S.Z.
author_sort Tan, P.C.
title A placebo-controlled trial of oral pyridoxine in hyperemesis gravidarum
title_short A placebo-controlled trial of oral pyridoxine in hyperemesis gravidarum
title_full A placebo-controlled trial of oral pyridoxine in hyperemesis gravidarum
title_fullStr A placebo-controlled trial of oral pyridoxine in hyperemesis gravidarum
title_full_unstemmed A placebo-controlled trial of oral pyridoxine in hyperemesis gravidarum
title_sort placebo-controlled trial of oral pyridoxine in hyperemesis gravidarum
publishDate 2009
url http://eprints.um.edu.my/10851/1/Tan-2009-A_Placebo-Controlled.pdf
http://eprints.um.edu.my/10851/
http://www.karger.com/Article/Pdf/181182
_version_ 1643688902684311552